Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma
Open Access
- 19 March 2024
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 202, 114023
Abstract
No abstract availableKeywords
Funding Information
- Kraeftens Bekaempelse
- Sundhedsstyrelsen
This publication has 30 references indexed in Scilit:
- 1156P Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcomeAnnals of Oncology, 2023
- Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profileEuropean Journal of Cancer, 2023
- Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanomaEuropean Journal of Cancer, 2021
- Adjuvant treatment for melanoma in clinical practice – Trial versus realityEuropean Journal of Cancer, 2021
- Immune checkpoint inhibitors in melanomaThe Lancet, 2021
- The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patientsCancer Epidemiology, 2021
- Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected MelanomaJAMA Oncology, 2021
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trialThe Lancet Oncology, 2020
- Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆Annals of Oncology, 2020
- The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trialsEuropean Journal of Cancer, 2017